Patents by Inventor Mark C. Sleevi

Mark C. Sleevi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Purifying insulin using cation exchange and reverse phase chromatography in the presence of an organic modifier and elevated temperature
    Patent number: 11198718
    Abstract: A process is described for purifying insulin and insulin analogs that comprises high-pressure liquid chromatography with an acidic cation exchange medium performed in the presence of a water miscible organic modifier and at an elevated temperature followed by reverse phase chromatography performed in the presence of a water miscible organic modifier and at an elevated temperature.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: December 14, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Allison D. Ortigosa, Michael P. Coleman, Shibu T. George, Michael A. Rauscher, Mark C. Sleevi, Kartoa Chow
  • Process for producing recombinant trypsin
    Patent number: 10947521
    Abstract: A process for producing recombinant trypsin from prokaryote host cells in high yield and high specific activity is described. In particular, a process for producing recombinant trypsin from E. coli is described.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 16, 2021
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Mark C. Sleevi, Jack Lile
  • Process for obtaining insulin with correctly formed disulfide bonds
    Patent number: 10745457
    Abstract: A process for solubilization and refolding of precursor insulin or insulin analogs from inclusion body isolates for use in the production of insulin or insulin analog is described.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: August 18, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Allison D. Ortigosa, Rebecca A. Chmielowski, Mark C. Sleevi
  • PURIFYING INSULIN USING CATION EXCHANGE AND REVERSE PHASE CHROMATOGRAPHY IN THE PRESENCE OF AN ORGANIC MODIFIER AND ELEVATED TEMPERATURE
    Publication number: 20200010525
    Abstract: A process is described for purifying insulin and insulin analogs that comprises high-pressure liquid chromatography with an acidic cation exchange medium performed in the presence of a water miscible organic modifier and at an elevated temperature followed by reverse phase chromatography performed in the presence of a water miscible organic modifier and at an elevated temperature.
    Type: Application
    Filed: August 27, 2019
    Publication date: January 9, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Allison D. Ortigosa, Michael P. Coleman, Shibu T. George, Michael A. Rauscher, Mark C. Sleevi, Kartoa Chow
  • Process for purifying insulin and analogues thereof
    Patent number: 10421795
    Abstract: A process is described for purifying insulin and insulin analogs that comprises high-pressure liquid chromatography with an acidic cation exchange medium performed under low to moderate pressure at an elevated temperature.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 24, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael P. Coleman, Allison D. Ortigosa, Mark C. Sleevi, Kartoa Chow
  • Purifying insulin using cation exchange and reverse phase chromatography in the presence of an organic modifier and elevated temperature
    Patent number: 10407483
    Abstract: A process is described for purifying insulin and insulin analogs that comprises high-pressure liquid chromatography with an acidic cation exchange medium performed in the presence of a water miscible organic modifier and at an elevated temperature followed by reverse phase chromatography performed in the presence of a water miscible organic modifier and at an elevated temperature.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: September 10, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Allison D. Ortigosa, Michael P. Coleman, Shibu T. George, Michael A. Rauscher, Mark C. Sleevi, Kartoa Chow
  • Process for refolding recombinant chymotrypsin
    Patent number: 10301611
    Abstract: A process for refolding recombinant chymotrypsin produced from prokaryote host cells is described. In particular, the present invention provides a process for refolding recombinant chymotrypsin produced from E. coli is described.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: May 28, 2019
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Mark C. Sleevi, Jack Lile, Bryn Grimison
  • Method for preparing crystalline insulin or insulin analog compositions
    Patent number: 10124040
    Abstract: A method for crystallizing insulin or insulin analogs under alkaline conditions in the presence of zinc, purifying the crystals by filtering through a filter, and drying the crystals captured on the filter to produce crystalline insulin or insulin analog compositions is described. Method has been exemplified with insulin lispro.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: November 13, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Douglas S. Watson, Allison C. Ortigosa, Mark C. Sleevi, Kathryn M. Story
  • A PROCESS FOR OBTAINING INSULIN WITH CORRECTLY FORMED DISULFIDE BONDS
    Publication number: 20180244744
    Abstract: A process for solubilization and refolding of precursor insulin or insulin analogs from inclusion body isolates for use in the production of insulin or insulin analog is described.
    Type: Application
    Filed: August 29, 2016
    Publication date: August 30, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Allison D. Ortigosa, Rebecca A. Chmielowski, Mark C. Sleevi
  • PROCESS FOR REFOLDING RECOMBINANT CHYMOTRYPSIN
    Publication number: 20170342397
    Abstract: A process for refolding recombinant chymotrypsin produced from prokaryote host cells is described. In particular, the present invention provides a process for refolding recombinant chymotrypsin produced from E. coli is described.
    Type: Application
    Filed: November 13, 2015
    Publication date: November 30, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mark C. Sleevi, Jack Lile, Bryn Grimison
  • PROCESS FOR PRODUCING RECOMBINANT TRYPSIN
    Publication number: 20170335308
    Abstract: A process for producing recombinant trypsin from prokaryote host cells in high yield and high specific activity is described. In particular, a process for producing recombinant trypsin from E. coli is described.
    Type: Application
    Filed: November 13, 2015
    Publication date: November 23, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mark C. Sleevi, Jack Lile
  • Method for preparing crystalline insulin
    Patent number: 9822158
    Abstract: A method for crystallizing insulin or insulin analogs under alkaline conditions and purifying the insulin or insulin analog crystals by filtering through a filter and drying the insulin or insulin analog crystals captured on the filter to produce crystalline insulin or insulin analog crystal compositions is described. In particular aspects, the method may be used to crystalize insulin glargine.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: November 21, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Allison D. Ortigosa, William Perry, Mark C. Sleevi, Luis Sierra
  • METHOD FOR PREPARING CRYSTALLINE INSULIN OR INSULIN ANALOG COMPOSITIONS
    Publication number: 20170209545
    Abstract: A method for crystallizing insulin or insulin analogs under alkaline conditions in the presence of zinc, purifying the crystals by filtering through a filter, and drying the crystals captured on the filter to produce crystalline insulin or insulin analog compositions is described. Method has been exemplified with insulin lispro.
    Type: Application
    Filed: August 21, 2015
    Publication date: July 27, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Douglas S. Watson, Allison C. Ortigosa, Mark C. Sleevi, Kathryn M. Story
  • PURIFYING INSULIN USING CATION EXCHANGE AND REVERSE PHASE CHROMATOGRAPHY IN THE PRESENCE OF AN ORGANIC MODIFIER AND ELEVATED TEMPERATURE
    Publication number: 20170015725
    Abstract: A process is described for purifying insulin and insulin analogs that comprises high-pressure liquid chromatography with an acidic cation exchange medium performed in the presence of a water miscible organic modifier and at an elevated temperature followed by reverse phase chromatography performed in the presence of a water miscible organic modifier and at an elevated temperature.
    Type: Application
    Filed: March 11, 2015
    Publication date: January 19, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Allison D. Ortigosa, Michael P. Coleman, Shibu T. George, Michael A. Rauscher, Mark C. Sleevi, Kartoa Chow
  • METHOD FOR PREPARING CRYSTALLINE INSULIN
    Publication number: 20160297862
    Abstract: A method for crystallizing insulin or insulin analogs under alkaline conditions and purifying the insulin or insulin analog crystals by filtering through a filter and drying the insulin or insulin analog crystals captured on the filter to produce crystalline insulin or insulin analog crystal compositions is described. In particular aspects, the method may be used to crystalize insulin glargine.
    Type: Application
    Filed: December 1, 2014
    Publication date: October 13, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Allison D. Ortigosa, William Perry, Mark C. Sleevi, Luis Sierra
  • PROCESS FOR PURIFYING INSULIN AND ANALOGUES THEREOF
    Publication number: 20150329612
    Abstract: A process is described for purifying insulin and insulin analogues that comprises high-pressure liquid chromatography with an acidic cation exchange medium performed under low to moderate pressure at an elevated temperature.
    Type: Application
    Filed: December 12, 2013
    Publication date: November 19, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael P. COLEMAN, Allison D. ORTIGOSA, Mark C. SLEEVI, Kartoa CHOW
  • Purified rhIGF-I/rhIGFBP-3 complexes and their method of manufacture
    Patent number: 7968679
    Abstract: Complexes of IGF-I and IGFBP-3 with new levels of purity are provided. Chromatographic techniques have been developed that remove contaminants, such as mass and charge variants of IGFBP-3. The new techniques enable the production of high-quality pharmaceutical compositions comprising IGF-I/IGFBP-3 complexes.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: June 28, 2011
    Assignee: Insmed Incorporated
    Inventors: Mark C. Sleevi, Glen L. Kelley
  • Methods for the production of D-chiro-inositol and the use of D-chiro inositol obtained therefrom
    Patent number: 6660891
    Abstract: The present invention relates to methods for the production and isolation of D-chiro-inositol (DCI) from plant extracts. Specifically the present invention provides a method to produce D-chiro-inositol from a precursor moiety by conversion in concentrated hydrochloric acid. More specifically, the present invention relates to a method for the efficient production of DCI by a process involving the extraction of D-pinitol from soy hulls followed by conversion thereof to DCI.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: December 9, 2003
    Assignee: Insmed Incorporated
    Inventors: Leland L. Johnson, Jr., Mark C. Sleevi, A. S. Campbell, Robert Plourde, Patrick Leonard, Paul Miller
  • Methods for the production of D-chiro-inositol and the use of D-chiro-inositol obtained therefrom
    Publication number: 20020023877
    Abstract: The present invention relates to methods for the production and isolation of D-chiro-inositol (DCI) from plant extracts. Specifically the present invention provides a method to produce D-chiro-inositol from a precursor moiety by conversion in concentrated hydrochloric acid. More specifically, the present invention relates to a method for the efficient production of DCI by a process involving the extraction of D-pinitol from soy hulls followed by conversion thereof to DCI.
    Type: Application
    Filed: May 11, 2001
    Publication date: February 28, 2002
    Inventors: Leland L. Johnson, Mark C. Sleevi, A. S. Campbell, Robert Plourde, Patrick Leonard, Paul Miller
  • Methods for the production and isolation of D-chiro-inositol from kasugamycin and the use of D-chiro-inositol obtained therefrom
    Patent number: 6342645
    Abstract: The present invention relates to methods for the production and isolation of D-chiro-inositol (DCI) from kasugamycin. More specifically, the present invention relates to a method of producing DCI by hydrolysis of kasugamycin with aqueous trifluoroacetic acid in the presence of a strongly acidic ion exchange resin. The present invention further relates to methods of isolating DCI from an aqueous mixture, such as a hydrolysis mixture, either directly or by forming an organic derivative of DCI.
    Type: Grant
    Filed: December 29, 2000
    Date of Patent: January 29, 2002
    Assignee: Insmed Pharmaceuticals, Inc.
    Inventors: Robert Plourde, Jr., Mark C. Sleevi, Rachel K. Longo